BVF Inc reported 42 positions worth $2.97B for the quarter ended Sep 30, 2026, down 16.9% on the prior quarter. It opened 2 new positions, added to 6, trimmed 15 and exited 0. Its largest holding is Revolution Medicines, Inc. at 17% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| TYRA Tyra Biosciences, Inc. | +2.74M | +185.6% | $59.92M | 3.1% |
| ALKS Alkermes plc. | +692.4K | +32.1% | $28.06M | 3.88% |
| STOK Stoke Therapeutics, Inc. | +1.06M | +41.7% | $27.60M | 3.16% |
| PYXS Pyxis Oncology, Inc. | +11.83M | – | $27.55M | 0.927% |
| ALEC Alector, Inc. | +10.05M | – | $18.59M | 0.625% |
| SGMT Sagimet Biosciences Inc. | +1.00M | +40.0% | $9.88M | 1.16% |
| CBIO Crescent Biopharma, Inc. | +344.8K | +12.5% | $5.03M | 1.52% |
| OKUR OnKure Therapeutics, Inc. | +809.5K | +25.0% | $2.21M | 0.371% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. | -504.6K | -17.0% | $103.57M | 16.99% |
| IRON Disc Medicine, Inc. | -920.3K | -79.8% | $60.24M | 0.514% |
| MIRM Mirum Pharmaceuticals, Inc. | -648.8K | -61.4% | $55.46M | 1.17% |
| XNCR Xencor Inc | -906.7K | -12.7% | $22.62M | 5.23% |
| GPCR Structure Therapeutics Inc. | -675.4K | -20.1% | $21.12M | 2.83% |
| KURA Kura Oncology, Inc. | -1.76M | -20.8% | $18.80M | 2.41% |
| AVTX Avalo Therapeutics, Inc. | -1.17M | -56.3% | $17.91M | 0.468% |
| NKTR Nektar Therapeutics | -257.1K | -10.8% | $15.56M | 4.35% |
| PVLA Palvella Therapeutics, Inc. | -65.6K | -9.8% | $9.05M | 2.82% |
| ZYME Zymeworks Inc. | -185.0K | -5.1% | $4.90M | 3.09% |
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | RVMD Revolution Medicines, Inc. | Healthcare | 2.46M | $505.05M | 16.99% | -504.6K | -17.0% | Reduced | 1.14% |
| 2 | KYMR Kymera Therapeutics, Inc. | Healthcare | 3.87M | $432.86M | 14.56% | 0 | 0.0% | Unchanged | 3.87% |
| 3 | GHRS GH Research PLC | Healthcare | 8.65M | $203.11M | 6.83% | 0 | 0.0% | Unchanged | 12.6% |
| 4 | MLTX MoonLake Immunotherapeutics | Healthcare | 16.00M | $187.22M | 6.3% | 0 | 0.0% | Unchanged | 18.74% |
| 5 | XNCR Xencor Inc | Healthcare | 6.23M | $155.36M | 5.23% | -906.7K | -12.7% | Reduced | 8.17% |
| 6 | NKTR Nektar Therapeutics | Healthcare | 2.13M | $129.20M | 4.35% | -257.1K | -10.8% | Reduced | 6.24% |
| 7 | ALKS Alkermes plc. | Healthcare | 2.85M | $115.36M | 3.88% | +692.4K | +32.1% | Added | 1.69% |
| 8 | STOK Stoke Therapeutics, Inc. | Healthcare | 3.61M | $93.83M | 3.16% | +1.06M | +41.7% | Added | 5.28% |
| 9 | TYRA Tyra Biosciences, Inc. | Healthcare | 4.22M | $92.20M | 3.1% | +2.74M | +185.6% | Added | 6.1% |
| 10 | ZYME Zymeworks Inc. | Healthcare | 3.46M | $91.77M | 3.09% | -185.0K | -5.1% | Reduced | 4.84% |
| 11 | CGEM Cullinan Therapeutics, Inc. | Healthcare | 5.75M | $88.27M | 2.97% | 0 | 0.0% | Unchanged | 8.86% |
| 12 | GPCR Structure Therapeutics Inc. | Healthcare | 2.69M | $84.16M | 2.83% | -675.4K | -20.1% | Reduced | 3.77% |
| 13 | PVLA Palvella Therapeutics, Inc. | Healthcare | 607.1K | $83.74M | 2.82% | -65.6K | -9.8% | Reduced | 4.16% |
| 14 | KURA Kura Oncology, Inc. | Healthcare | 6.69M | $71.65M | 2.41% | -1.76M | -20.8% | Reduced | 7.28% |
| 15 | ACIU AC Immune SA | Healthcare | 19.82M | $51.93M | 1.75% | 0 | 0.0% | Unchanged | 19.67% |
Tip. Select a row to see that position’s full history at Bvf.
As of its Q3 2026 13F filing, BVF Inc’s five largest positions were Revolution Medicines, Inc. (RVMD) at 17.0%, Kymera Therapeutics, Inc. (KYMR) at 14.6%, GH Research PLC (GHRS) at 6.8%, MoonLake Immunotherapeutics (MLTX) at 6.3%, Xencor Inc (XNCR) at 5.2% of the reported portfolio.
BVF Inc reported a 13F portfolio worth $2.97B across 42 positions for Q3 2026. That is down 16.9% from the previous quarter.
Its largest purchases by value were Tyra Biosciences, Inc. ($59.92M), Alkermes plc. ($28.06M), Stoke Therapeutics, Inc. ($27.60M). It opened 2 new positions.
Its largest sales by value were Revolution Medicines, Inc. ($103.57M), Disc Medicine, Inc. ($60.24M), Mirum Pharmaceuticals, Inc. ($55.46M). It exited 0 positions entirely.
From the Form 13F-HR reports BVF Inc files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.